Review



agena massarray sars cov 2 variant panel v3  (agena bioscience)


Bioz Verified Symbol agena bioscience is a verified supplier
Bioz Manufacturer Symbol agena bioscience manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    agena bioscience agena massarray sars cov 2 variant panel v3
    Detection of viral variants by the Agena <t>MassARRAY</t> SARS-CoV-2 Variant Panel. (A) SARS-CoV-2 genome with nucleotide positions from 5′-to-3′ direction depicted above. S gene polymorphisms targeted by the variant panel (lollipops) and corresponding amino acids are depicted below. (B) A color map depicts algorithms of target combinations that defined 16 distinct SARS-CoV-2 variants on the panel. Variant results are depicted (left) and included the WHO designation (e.g., Omicron, Delta, etc.) and corresponding PANGO lineage assignments. Note that the B.1.526.1 variant was redesignated B.1.637 to distinguish it from the Iota variant lineage ( https://cov-lineages.org/lineage_list.html , accessed April 26, 2022). The minimum number of targets required to support the corresponding variant result is indicated (right). Target results are depicted as colored cells indicating amino acid positions that did not contribute to the defined variant identity algorithm (gray). The remaining three colors reflect native amino acids (e.g., unchanged from Wuhan-Hu-1 reference) (yellow), detectable amino acid polymorphisms (red), and drop out of the given target (green), all of which contributed to the variant identity algorithm. (C) Phylogenetic composition of 391 clinical specimen viral RNA recovered for diagnostic evaluation of the variant panel. The numbers of each lineage tested are depicted in brackets.
    Agena Massarray Sars Cov 2 Variant Panel V3, supplied by agena bioscience, used in various techniques. Bioz Stars score: 97/100, based on 25 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+detection/MassARRAY+SARS-CoV-2+Variant+Panel+Set/pmc09604185-206-17-24
    Average 97 stars, based on 25 article reviews
    agena massarray sars cov 2 variant panel v3 - by Bioz Stars, 2026-11
    97/100 stars

    Images

    1) Product Images from "A Robust, Highly Multiplexed Mass Spectrometry Assay to Identify SARS-CoV-2 Variants"

    Article Title: A Robust, Highly Multiplexed Mass Spectrometry Assay to Identify SARS-CoV-2 Variants

    Journal: Microbiology Spectrum

    doi: 10.1128/spectrum.01736-22

    Detection of viral variants by the Agena MassARRAY SARS-CoV-2 Variant Panel. (A) SARS-CoV-2 genome with nucleotide positions from 5′-to-3′ direction depicted above. S gene polymorphisms targeted by the variant panel (lollipops) and corresponding amino acids are depicted below. (B) A color map depicts algorithms of target combinations that defined 16 distinct SARS-CoV-2 variants on the panel. Variant results are depicted (left) and included the WHO designation (e.g., Omicron, Delta, etc.) and corresponding PANGO lineage assignments. Note that the B.1.526.1 variant was redesignated B.1.637 to distinguish it from the Iota variant lineage ( https://cov-lineages.org/lineage_list.html , accessed April 26, 2022). The minimum number of targets required to support the corresponding variant result is indicated (right). Target results are depicted as colored cells indicating amino acid positions that did not contribute to the defined variant identity algorithm (gray). The remaining three colors reflect native amino acids (e.g., unchanged from Wuhan-Hu-1 reference) (yellow), detectable amino acid polymorphisms (red), and drop out of the given target (green), all of which contributed to the variant identity algorithm. (C) Phylogenetic composition of 391 clinical specimen viral RNA recovered for diagnostic evaluation of the variant panel. The numbers of each lineage tested are depicted in brackets.
    Figure Legend Snippet: Detection of viral variants by the Agena MassARRAY SARS-CoV-2 Variant Panel. (A) SARS-CoV-2 genome with nucleotide positions from 5′-to-3′ direction depicted above. S gene polymorphisms targeted by the variant panel (lollipops) and corresponding amino acids are depicted below. (B) A color map depicts algorithms of target combinations that defined 16 distinct SARS-CoV-2 variants on the panel. Variant results are depicted (left) and included the WHO designation (e.g., Omicron, Delta, etc.) and corresponding PANGO lineage assignments. Note that the B.1.526.1 variant was redesignated B.1.637 to distinguish it from the Iota variant lineage ( https://cov-lineages.org/lineage_list.html , accessed April 26, 2022). The minimum number of targets required to support the corresponding variant result is indicated (right). Target results are depicted as colored cells indicating amino acid positions that did not contribute to the defined variant identity algorithm (gray). The remaining three colors reflect native amino acids (e.g., unchanged from Wuhan-Hu-1 reference) (yellow), detectable amino acid polymorphisms (red), and drop out of the given target (green), all of which contributed to the variant identity algorithm. (C) Phylogenetic composition of 391 clinical specimen viral RNA recovered for diagnostic evaluation of the variant panel. The numbers of each lineage tested are depicted in brackets.

    Techniques Used: Variant Assay, Diagnostic Assay

    Diagnostic sensitivity and specificity of the Agena MassARRAY SARS-CoV-2 Variant panel. (A) Diagnostic sensitivity and (B) diagnostic specificity of 11 variant calls on the panel are depicted. The number of specimens that correspond with each variant according to WGS is annotated in brackets. Depiction of (C) diagnostic sensitivity and (D) diagnostic specificity of each of 30 distinct panel targets. The number of specimens that correspond with each amino acid polymorphism according to WGS is annotated in brackets for each target. Asterisks (*) indicate targets for which dropout results were excluded from analyses (see Materials and Methods). For target N501Y, a separate diagnostic analysis was conducted excluding BA.1 specimens (“N501Y_Excl-BA.1”). Error bars reflect 95% CI in all four panels. ND, not determined.
    Figure Legend Snippet: Diagnostic sensitivity and specificity of the Agena MassARRAY SARS-CoV-2 Variant panel. (A) Diagnostic sensitivity and (B) diagnostic specificity of 11 variant calls on the panel are depicted. The number of specimens that correspond with each variant according to WGS is annotated in brackets. Depiction of (C) diagnostic sensitivity and (D) diagnostic specificity of each of 30 distinct panel targets. The number of specimens that correspond with each amino acid polymorphism according to WGS is annotated in brackets for each target. Asterisks (*) indicate targets for which dropout results were excluded from analyses (see Materials and Methods). For target N501Y, a separate diagnostic analysis was conducted excluding BA.1 specimens (“N501Y_Excl-BA.1”). Error bars reflect 95% CI in all four panels. ND, not determined.

    Techniques Used: Diagnostic Assay, Variant Assay

    Target result patterns of undefined variants on the Agena MassARRAY SARS-CoV-2 Variant Panel. (A) A color map depicts the observed target results for three undefined SARS-CoV-2 variants tested on the panel: Lambda (C.37), Mu (B.1.621), and Omicron (BA.2). Distinct target patterns were observed among each of the variant types are depicted. Cells indicate the distinct target results, including detectable native amino acid (gray), detection of target polymorphism (red), and target dropout (green). The number of specimens that yielded each of the distinct target result patterns is indicated on the right as well as the output variant ID result generated by the variant panel software. (B) A heatmap depicts the measured prevalence of each variant panel target substitution among publicly available Omicron sublineage genomes as of May 6, 2022.
    Figure Legend Snippet: Target result patterns of undefined variants on the Agena MassARRAY SARS-CoV-2 Variant Panel. (A) A color map depicts the observed target results for three undefined SARS-CoV-2 variants tested on the panel: Lambda (C.37), Mu (B.1.621), and Omicron (BA.2). Distinct target patterns were observed among each of the variant types are depicted. Cells indicate the distinct target results, including detectable native amino acid (gray), detection of target polymorphism (red), and target dropout (green). The number of specimens that yielded each of the distinct target result patterns is indicated on the right as well as the output variant ID result generated by the variant panel software. (B) A heatmap depicts the measured prevalence of each variant panel target substitution among publicly available Omicron sublineage genomes as of May 6, 2022.

    Techniques Used: Variant Assay, Generated, Software

    Related Articles

    Mutagenesis:

    Article Title: Rapid Evaluation of the Xpert ® Xpress CoV-2 plus and Xpert ® Xpress CoV-2/Flu/RSV plus Tests.
    Article Snippet: .. These specimens were selected by COVID-19 wave and were previously genotyped by the AllPlex SARS-CoV-2 Variants I and II and NovaPlex SARS-CoV-2 Variants V tests (all Seegene, Seoul, Republic of Korea) and/or TaqMan SARS-CoV-2 Mutation Panels (Thermo Fisher Scientific, Waltham, MA, USA) and/or MassARRAY SARS-CoV-2 Variant Panel v3 (RUO) (MassARRAY; Agena Biosciences, San Diego, CA, USA), or by next generation sequencing performed at the NICD. .. In addition, AccuPlex SARS-CoV-2 variant reference material (LGC SeraCare, Milford, MA, USA) was selected from the AccuPlex SARS-CoV-2 Variants Panel 1 (Wuhan, Alpha, Beta and Gamma) and AccuPlex SARS-CoV-2 Variants Panel 2 (Delta) were used to assess the performance of the test on VOC material.

    Article Title: Rapid Evaluation of the Xpert ® Xpress CoV-2 plus and Xpert ® Xpress CoV-2/Flu/RSV plus Tests
    Article Snippet: .. These specimens were selected by COVID-19 wave and were previously genotyped by the AllPlex SARS-CoV-2 Variants I and II and NovaPlex SARS-CoV-2 Variants V tests (all Seegene, Seoul, Republic of Korea) and/or TaqMan SARS-CoV-2 Mutation Panels (Thermo Fisher Scientific, Waltham, MA, USA) and/or MassARRAY SARS-CoV-2 Variant Panel v3 (RUO) (MassARRAY; Agena Biosciences, San Diego, CA, USA), or by next generation sequencing performed at the NICD. .. In addition, AccuPlex SARS-CoV-2 variant reference material (LGC SeraCare, Milford, MA, USA) was selected from the AccuPlex SARS-CoV-2 Variants Panel 1 (Wuhan, Alpha, Beta and Gamma) and AccuPlex SARS-CoV-2 Variants Panel 2 (Delta) were used to assess the performance of the test on VOC material.

    Variant Assay:

    Article Title: Rapid Evaluation of the Xpert ® Xpress CoV-2 plus and Xpert ® Xpress CoV-2/Flu/RSV plus Tests.
    Article Snippet: .. These specimens were selected by COVID-19 wave and were previously genotyped by the AllPlex SARS-CoV-2 Variants I and II and NovaPlex SARS-CoV-2 Variants V tests (all Seegene, Seoul, Republic of Korea) and/or TaqMan SARS-CoV-2 Mutation Panels (Thermo Fisher Scientific, Waltham, MA, USA) and/or MassARRAY SARS-CoV-2 Variant Panel v3 (RUO) (MassARRAY; Agena Biosciences, San Diego, CA, USA), or by next generation sequencing performed at the NICD. .. In addition, AccuPlex SARS-CoV-2 variant reference material (LGC SeraCare, Milford, MA, USA) was selected from the AccuPlex SARS-CoV-2 Variants Panel 1 (Wuhan, Alpha, Beta and Gamma) and AccuPlex SARS-CoV-2 Variants Panel 2 (Delta) were used to assess the performance of the test on VOC material.

    Article Title: A robust, highly multiplexed mass spectrometry assay to identify SARS-CoV-2 variants
    Article Snippet: .. We recovered residual viral RNA from all 391 specimens from −80°C storage to undergo testing on the Agena MassARRAY ® SARS-CoV-2 Variant Panel v3 ( https://www.agenabio.com/products/panel/coronavirus-sars-cov-2-variant-detection-research-162panel/#:~:text=The%20MassARRAY%C2%AE%20SARS%2DCoV ,SARS%2DCoV%2D2%20variants., last accessed 4/25/22). ..

    Article Title: A Robust, Highly Multiplexed Mass Spectrometry Assay to Identify SARS-CoV-2 Variants
    Article Snippet: .. We recovered residual viral RNA from all 391 specimens from −80°C storage to undergo testing on the Agena MassARRAY SARS-CoV-2 Variant Panel v3 ( https://www.agenabio.com/products/panel/coronavirus-sars-cov-2-variant-detection-research-panel , accessed April 5, 2022). ..

    Article Title: Rapid Evaluation of the Xpert ® Xpress CoV-2 plus and Xpert ® Xpress CoV-2/Flu/RSV plus Tests
    Article Snippet: .. These specimens were selected by COVID-19 wave and were previously genotyped by the AllPlex SARS-CoV-2 Variants I and II and NovaPlex SARS-CoV-2 Variants V tests (all Seegene, Seoul, Republic of Korea) and/or TaqMan SARS-CoV-2 Mutation Panels (Thermo Fisher Scientific, Waltham, MA, USA) and/or MassARRAY SARS-CoV-2 Variant Panel v3 (RUO) (MassARRAY; Agena Biosciences, San Diego, CA, USA), or by next generation sequencing performed at the NICD. .. In addition, AccuPlex SARS-CoV-2 variant reference material (LGC SeraCare, Milford, MA, USA) was selected from the AccuPlex SARS-CoV-2 Variants Panel 1 (Wuhan, Alpha, Beta and Gamma) and AccuPlex SARS-CoV-2 Variants Panel 2 (Delta) were used to assess the performance of the test on VOC material.

    Article Title: A Robust, Highly Multiplexed Mass Spectrometry Assay to Identify SARS-CoV-2 Variants
    Article Snippet: .. Agena MassARRAY® SARS-CoV-2 Variant Panel v3 (RUO) results ID Collection Date GISAID Accession a PANGO Lineage (WGS) Agena Variant Results b Genetic Markers Detected c PV17741 9/2/20 EPI_ISL_802220 B.1.239 D614G Detected. ..

    Article Title: A robust, highly multiplexed mass spectrometry assay to identify SARS-CoV-2 variants
    Article Snippet: .. We assessed the diagnostic performance of the highly multiplexed Agena MassARRAY ® SARS-CoV-2 Variant Panel v3 to identify variants in a diverse set of 391 SARS-CoV-2 clinical RNA specimens collected across our health systems in New York City, USA as well as in Bogotá, Colombia (September 2, 2020 – March 2, 2022). ..

    Article Title: A robust, highly multiplexed mass spectrometry assay to identify SARS-CoV-2 variants
    Article Snippet: .. These specimens had previously undergone WGS for epidemiologic surveillance, and we used this data as a benchmark to evaluate the diagnostic performance of the Agena MassARRAY ® SARS-CoV-2 Variant Panel v3 (research use only, RUO). ..

    Next-Generation Sequencing:

    Article Title: Rapid Evaluation of the Xpert ® Xpress CoV-2 plus and Xpert ® Xpress CoV-2/Flu/RSV plus Tests.
    Article Snippet: .. These specimens were selected by COVID-19 wave and were previously genotyped by the AllPlex SARS-CoV-2 Variants I and II and NovaPlex SARS-CoV-2 Variants V tests (all Seegene, Seoul, Republic of Korea) and/or TaqMan SARS-CoV-2 Mutation Panels (Thermo Fisher Scientific, Waltham, MA, USA) and/or MassARRAY SARS-CoV-2 Variant Panel v3 (RUO) (MassARRAY; Agena Biosciences, San Diego, CA, USA), or by next generation sequencing performed at the NICD. .. In addition, AccuPlex SARS-CoV-2 variant reference material (LGC SeraCare, Milford, MA, USA) was selected from the AccuPlex SARS-CoV-2 Variants Panel 1 (Wuhan, Alpha, Beta and Gamma) and AccuPlex SARS-CoV-2 Variants Panel 2 (Delta) were used to assess the performance of the test on VOC material.

    Article Title: Rapid Evaluation of the Xpert ® Xpress CoV-2 plus and Xpert ® Xpress CoV-2/Flu/RSV plus Tests
    Article Snippet: .. These specimens were selected by COVID-19 wave and were previously genotyped by the AllPlex SARS-CoV-2 Variants I and II and NovaPlex SARS-CoV-2 Variants V tests (all Seegene, Seoul, Republic of Korea) and/or TaqMan SARS-CoV-2 Mutation Panels (Thermo Fisher Scientific, Waltham, MA, USA) and/or MassARRAY SARS-CoV-2 Variant Panel v3 (RUO) (MassARRAY; Agena Biosciences, San Diego, CA, USA), or by next generation sequencing performed at the NICD. .. In addition, AccuPlex SARS-CoV-2 variant reference material (LGC SeraCare, Milford, MA, USA) was selected from the AccuPlex SARS-CoV-2 Variants Panel 1 (Wuhan, Alpha, Beta and Gamma) and AccuPlex SARS-CoV-2 Variants Panel 2 (Delta) were used to assess the performance of the test on VOC material.

    Whole Complete genome sequencing:

    Article Title: A Robust, Highly Multiplexed Mass Spectrometry Assay to Identify SARS-CoV-2 Variants
    Article Snippet: .. Agena MassARRAY® SARS-CoV-2 Variant Panel v3 (RUO) results ID Collection Date GISAID Accession a PANGO Lineage (WGS) Agena Variant Results b Genetic Markers Detected c PV17741 9/2/20 EPI_ISL_802220 B.1.239 D614G Detected. ..

    Article Title: A robust, highly multiplexed mass spectrometry assay to identify SARS-CoV-2 variants
    Article Snippet: .. These specimens had previously undergone WGS for epidemiologic surveillance, and we used this data as a benchmark to evaluate the diagnostic performance of the Agena MassARRAY ® SARS-CoV-2 Variant Panel v3 (research use only, RUO). ..

    Diagnostic Assay:

    Article Title: A robust, highly multiplexed mass spectrometry assay to identify SARS-CoV-2 variants
    Article Snippet: .. We assessed the diagnostic performance of the highly multiplexed Agena MassARRAY ® SARS-CoV-2 Variant Panel v3 to identify variants in a diverse set of 391 SARS-CoV-2 clinical RNA specimens collected across our health systems in New York City, USA as well as in Bogotá, Colombia (September 2, 2020 – March 2, 2022). ..

    Article Title: A robust, highly multiplexed mass spectrometry assay to identify SARS-CoV-2 variants
    Article Snippet: .. These specimens had previously undergone WGS for epidemiologic surveillance, and we used this data as a benchmark to evaluate the diagnostic performance of the Agena MassARRAY ® SARS-CoV-2 Variant Panel v3 (research use only, RUO). ..



    Similar Products

    90
    agena bioscience massarray detection platform
    Massarray Detection Platform, supplied by agena bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+detection/massarray+platform/pmc09910734-173-0-3
    Average 90 stars, based on 1 article reviews
    massarray detection platform - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    agena bioscience kit for the qualitative detection of sars-cov-2 using rt-pcr reaction together with the massarray system
    Kit For The Qualitative Detection Of Sars Cov 2 Using Rt Pcr Reaction Together With The Massarray System, supplied by agena bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+detection/massarray+sars+cov+2+panel/pm36747014-37-9-18
    Average 90 stars, based on 1 article reviews
    kit for the qualitative detection of sars-cov-2 using rt-pcr reaction together with the massarray system - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    agena bioscience commercial kit for the qualitative detection of sars-cov-2 using rt-pcr reaction together with the massarray system
    Comparison of SARS-CoV-2 variant identification using Next Generation Sequencing (NGS) and MassARRY PMA-ABDO and PMA-Omicron (n = 358).
    Commercial Kit For The Qualitative Detection Of Sars Cov 2 Using Rt Pcr Reaction Together With The Massarray System, supplied by agena bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+detection/massarray+sars+cov+2+panel/pmc09900542-103-9-18
    Average 90 stars, based on 1 article reviews
    commercial kit for the qualitative detection of sars-cov-2 using rt-pcr reaction together with the massarray system - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Sequenom iplex® gold massarray maldi-tof ms detection
    Comparison of SARS-CoV-2 variant identification using Next Generation Sequencing (NGS) and MassARRY PMA-ABDO and PMA-Omicron (n = 358).
    Iplex® Gold Massarray Maldi Tof Ms Detection, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+detection/maldi+tof+mass+spectrometry+iplex+platform/pmc04299921-50-6-5
    Average 90 stars, based on 1 article reviews
    iplex® gold massarray maldi-tof ms detection - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    96
    agena bioscience agena massarray methylation detection
    Comparison of SARS-CoV-2 variant identification using Next Generation Sequencing (NGS) and MassARRY PMA-ABDO and PMA-Omicron (n = 358).
    Agena Massarray Methylation Detection, supplied by agena bioscience, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+detection/Methylation/ppr0552502-125-0-0
    Average 96 stars, based on 1 article reviews
    agena massarray methylation detection - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    90
    Sequenom massarray methylation detection
    A A negative correlation between ZNF334 <t>methylation</t> level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
    Massarray Methylation Detection, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+detection/massarray+quantitative+methylation+analysis/pmc09085879-231-0-4
    Average 90 stars, based on 1 article reviews
    massarray methylation detection - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Sequenom massarray sequenom detection
    A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
    Massarray Sequenom Detection, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+detection/sequenom+massarray/pmc09085879-184-7-8
    Average 90 stars, based on 1 article reviews
    massarray sequenom detection - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    agena bioscience massarray dna mass spectrometry detection
    A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
    Massarray Dna Mass Spectrometry Detection, supplied by agena bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+detection/massarray+mass+spectrometer/pm34260825-63-8-13
    Average 90 stars, based on 1 article reviews
    massarray dna mass spectrometry detection - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Sequenom massarray snp detection
    A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
    Massarray Snp Detection, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+detection/sequenom+massarray/pmc08787141-153-1-0
    Average 90 stars, based on 1 article reviews
    massarray snp detection - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    Image Search Results


    Comparison of SARS-CoV-2 variant identification using Next Generation Sequencing (NGS) and MassARRY PMA-ABDO and PMA-Omicron (n = 358).

    Journal: Scientific Reports

    Article Title: Simultaneous detection of omicron and other SARS-CoV-2 variants by multiplex PCR MassARRAY technology

    doi: 10.1038/s41598-023-28715-9

    Figure Lengend Snippet: Comparison of SARS-CoV-2 variant identification using Next Generation Sequencing (NGS) and MassARRY PMA-ABDO and PMA-Omicron (n = 358).

    Article Snippet: Recently, the commercial kit for the qualitative detection of SARS-CoV-2 using RT-PCR reaction together with the MassARRAY system (Agena Bioscience ® , San Diego, CA, USA) has been developed, and it showed superiority over Real-time PCR assay .

    Techniques: Comparison, Variant Assay, Next-Generation Sequencing

    A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the MassARRAY methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.

    Journal: Cell Death & Disease

    Article Title: DNA hypermethylation modification promotes the development of hepatocellular carcinoma by depressing the tumor suppressor gene ZNF334

    doi: 10.1038/s41419-022-04895-6

    Figure Lengend Snippet: A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the MassARRAY methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.

    Article Snippet: MassARRAY methylation detection technology (Sequenom, USA) performed by CapitalBio Technology (Shanghai, China) was used to detect the methylation level of ZNF334 promoter (human) in carcinoma and paracancerous tissues of 25 HCC patients and Zfp334 promoter (mice) in treatment and control group.

    Techniques: Methylation, Expressing, Western Blot, Mass Spectrometry, Sequencing

    A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the MassARRAY methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.

    Journal: Cell Death & Disease

    Article Title: DNA hypermethylation modification promotes the development of hepatocellular carcinoma by depressing the tumor suppressor gene ZNF334

    doi: 10.1038/s41419-022-04895-6

    Figure Lengend Snippet: A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the MassARRAY methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.

    Article Snippet: And meanwhile, in clinical samples, we used MassArray Sequenom detection to further verify the DNA methylation changes of ZNF334 promoter in cancerous tissues and adjacent tissues.

    Techniques: Methylation, Expressing, Western Blot, Mass Spectrometry, Sequencing